pharmaphorum

MAY 13, 2022

The unprecedented rate of digital acceleration seen in the first two years of COVID-19 has set in train an age of digital transformation. In my last article, I outlined the inflection point facing the pharmaceutical industry in digital health and the digital transformation of its clinical and commercial operations. This time I’m going to focus on one company and its view on pharma’s digital commercial strategy.

Pharmaceutical Companies 127

Pharmaceutical Companies Pharmaceutical Companies Vaccines FDA 127

Pharma Mirror

MAY 13, 2022

Rockville, Emmes – a global, full-service Contract Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, announces that it will introduce to market its third generation version of Advantage eClinical at Society for Clinical Trials (SCT) in San Diego, May 15th – 18th. The cloud platform of Advantage eClinical will be available as a standalone software product after undergoing more than two years of development.

52

52

pharmaphorum

MAY 13, 2022

When it comes to enthusiasm about digital innovation, pharma seems to be more adept at talking the talk than walking the walk, as it were. That’s according to recent survey data from digital agency Graphite. Working with Reuters Events, the agency surveyed 450 healthcare executives, 85% of whom worked in pharma. A full 92% of the survey respondents agreed with the statement “Pharma-sponsored digital products can add value to the healthcare provider and patient by supporting the overall customer

103

103

Pharma Marketing Network

MAY 13, 2022

WOTY stands for Woman of the Year. I am excited to share a little bit about what the Healthcare Businesswomen’s Association’s WOTY event of 2022 is and my personal experience. Words that come to mind: #Inspirational #Aspiration and #Community. This was my first WOTY and my first in person event in 2 years! I bought a new dress and shoes (which killed my feet and ended up carrying around in a reusable bag!

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 13, 2022

Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter’s once-daily oral therapy Ryeqo, after NICE backed the GnRH antagonist to treat heavy menstrual bleeding associated with uterine fibroids. Ryeqo (relugolix/estradiol/norethisterone acetate) – originally developed by Myovant – is the first drug in the class to be approved for NHS use in this indication, offering another option to treatment with injectable GnRH drugs used for women with moderate to severe symptom

64

64

Pharma Times

MAY 13, 2022

The therapy offers patients a convenient alternative to surgery or injections and can be administered at home

37

37

Pharma Times

MAY 13, 2022

Data shows that 1.

40

40

pharmaphorum

MAY 13, 2022

The FDA has delivered a blow to UCB’s late-stage pipeline, after saying it is unable to approve its latecomer IL-17 inhibitor bimekizumab for moderate-to-severe plaque psoriasis. The Belgian biotech said today it had received a complete response letter from the US regulator saying it “cannot approve the application in its current form” because observations in FDA inspections have to be resolved beforehand.

FDA 52

FDA 52

pharmaphorum

MAY 13, 2022

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche’s rival drug. In its first-quarter update, iTeos said it assessing “how best to proceed with additional clinical development” of the anti-TIGIT antibody, although chief executive Michel Detheux insisted the company had been heartened by data reported at the AACR congress last month. “A

Immunization 52

Immunization 52

pharmaphorum

MAY 13, 2022

Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk – accusing them of deceptively driving up the price of the medicines. It has filed a lawsuit that accuses the drugmakers and pharmacy benefit managers Express Scripts, Caremark and OptumRx of conspiring to manipulate and inflate insulin prices in the state, inflating their profits and making the drugs unaffordable for many diabetics.

59

59

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA